Sivastin

Quick links to important sections

Sivastin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sivastin

Property Description
Active ingredient Simvastatin
Form Film-coated tablet (Oral medication)
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Managing high blood cholesterol
Origin Synthetic compound (Prodrug)

Sivastin is a medicine containing the active ingredient Simvastatin, which is classified definitively as an HMG-CoA reductase inhibitor, generally recognized as a statin. The primary purpose of this drug class is to systematically control and reduce abnormally high concentrations of cholesterol and other fats (lipids) in the bloodstream. Simvastatin is effective in lowering elevated total and LDL cholesterol. This means the medicine is an established tool for addressing fundamental lipid imbalances, and it is clinically recognized for its benefit in patients requiring consistent lipid management. Simvastatin is a synthetic compound that functions as a prodrug, converting into its therapeutically active form only after metabolism.

Composition and Pharmaceutical Form of Sivastin

The medication is supplied as a single-ingredient product and is intended for the oral route of administration as a film-coated tablet. The active substance, Simvastatin, is a cornerstone of this formulation and is prescribed as a prescription-only medicine (Rx), underscoring the necessity of medical oversight during its use. The active substance, Simvastatin, operates by targeting the liver, which is the body's main site of cholesterol production.

How Simvastatin Generally Helps the Body

Simvastatin achieves its therapeutic effect by selectively inhibiting the activity of the rate-limiting enzyme HMG-CoA reductase. By disrupting this internal production, the medication prompts liver cells to enhance the removal of harmful low-density lipoprotein (LDL) cholesterol from the circulating blood. This targeted mechanism confirms its general benefit in supporting a healthier, stable blood lipid profile in a typical use scenario for adults with high cholesterol.

Regulatory References

  1. Simvastatin: MedlinePlus Drug Information
  2. Simvastatin EPAR Summary

What side effects are possible with Sivastin?

Possible Side Effects and Safety Information

The regulatory safety profile for Sivastin (Simvastatin) organizes potential adverse reactions according to the body system affected and their reported frequency, based on official documents such as the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Adverse Reaction Categories

Side effects are primarily classified by the System-Organ Class involved, including Musculoskeletal, Hepatobiliary, Nervous System, and Gastrointestinal disorders. Common reactions generally include headache, constipation, and abdominal pain.

Serious Adverse Reactions

Official labeling specifically highlights the importance of rare but serious reactions.

Category Examples (as documented in labels)
Musculoskeletal Rhabdomyolysis (severe muscle breakdown), Immune-mediated necrotising myopathy
Hepatobiliary Fatal and non-fatal hepatic failure, Hepatitis/Jaundice
Immune Anaphylaxis, Hypersensitivity syndrome (e.g., Angioedema)

Safety Considerations and Restrictions

The safety profile defines limitations for specific populations and contexts. Age (mathbf65 years and older) and renal impairment are documented as predisposing factors for myopathy and rhabdomyolysis.

Use is formally contraindicated in the presence of active liver disease or persistent, unexplained elevations of liver enzymes. Furthermore, the risk of muscle injury is highest in the first year of treatment and is increased by concomitant use with certain medications, leading to regulatory restrictions on the mathbf80 mg dosage and specific drug-combination warnings.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory guidance strictly defines the actions required for a suspected Simvastatin (Sivastin) overdose, emphasizing that the effects are consistent with the drug’s known toxicities.


Documented Overdose Manifestations and Severe Outcomes

Experience with massive single-dose ingestion is limited, but documented presentations include signs of muscle injury, such as muscle pain, tenderness, or weakness (myopathy), and liver toxicity, identified by yellowing of the skin or eyes (hepatotoxicity). The most serious outcomes detailed in regulatory reports are rhabdomyolysis (severe muscle breakdown) and subsequent acute renal failure. Overdose risk factors include advanced age and renal impairment, which are listed as predisposing conditions for increased severity. Specific official guidance also addresses overdose risks in pediatric patients.


Immediate Actions and Supportive Management

Immediate medical attention must be sought for any suspected overdose, as mandated by regulatory authorities. The official regulatory profile confirms that no specific antidote is known for Simvastatin overdose. Management is symptomatic and supportive. If complications like myopathy are suspected, the drug must be immediately discontinued. Hospital monitoring is often required to manage severe effects and ensure timely intervention for potential acute renal failure.

Therapeutic Uses of Sivastin

Sivastin (simvastatin) is used as an adjunctive therapy, alongside appropriate diet and exercise, to help manage elevated fat and cholesterol levels in the blood. This treatment assists patients in achieving reduced levels of low-density lipoprotein (LDL) cholesterol and triglycerides, while also supporting an increase in high-density lipoprotein (HDL) cholesterol.

This medicine is commonly prescribed in clinical scenarios to address elevated blood lipids in conditions such as primary hyperlipidemia, mixed dyslipidemia, and familial hypercholesterolemia. By supporting the management of these conditions, Sivastin may assist in lowering the risk of a non-fatal heart attack, stroke, and the potential need for certain revascularization procedures. Lowering blood lipids with this medication is considered a component of a treatment plan to help manage the risk of experiencing cardiovascular events.


Quick Fact: Relief for Elevated Blood Lipids

Eligibility and Restrictions for Use

The eligibility for Sivastin (simvastatin) is strictly defined by regulatory documents, which establish clear restrictions based on specific health conditions, physiological states, and age.

Eligibility Scope

Field Official Regulatory Statement
Populations for whom use is allowed: Adults with primary hyperlipidemia or HoFH. Pediatric patients (aged 10 years and older) with HeFH under specific conditions.
Populations for whom use is contraindicated: Patients with active liver disease or unexplained persistent elevations of serum transaminases. Patients with known hypersensitivity to the drug.
Pregnancy and lactation eligibility status: Contraindicated in women who are pregnant or who may become pregnant, and in nursing mothers (breastfeeding).
Eligibility-related restrictions: The 80 mg daily dose is restricted to patients who have been taking it chronically (e.g., ge 12 months) without muscle toxicity; it must not be started in new patients. Patients with severe renal impairment require a reduced starting dose for eligibility.

What should I know about interactions with other medicines?

Simvastatin, the active ingredient in Sivastin, is known to participate in several formally documented interaction patterns. Its primary pharmacokinetic constraints stem from being a substrate for the metabolic enzyme CYP3A4 and the hepatic uptake transporter OATP1B1. Inhibition of these pathways significantly increases the systemic exposure of Simvastatin acid, which raises the documented risk of muscle-related adverse events.


Contraindicated Combinations and Dose Restrictions

Co-administration is contraindicated with strong inhibitors of CYP3A4, including certain azole antifungals, macrolide antibiotics, and HIV protease inhibitors, as well as with Cyclosporine, Danazol, and Gemfibrozil. For less potent inhibitors, regulatory labels mandate a maximum dose:

Interacting Substance Maximum Permitted Simvastatin Dose
Verapamil, Diltiazem, Dronedarone 10 mg once daily
Amiodarone, Amlodipine, Ranolazine 20 mg once daily

Other Pharmacodynamic and Product Interactions

Simvastatin's interaction profile also includes pharmacodynamic interactions, such as an increased risk of myopathy when co-administered with other fibrates or Colchicine. When taken with Coumarin Anticoagulants, Simvastatin may potentiate the effect, requiring monitoring. To maintain efficacy when co-administered with Bile Acid Sequestrants, Simvastatin must be taken at least 2 hours before or 4 hours after the sequestrant. Finally, consumption of large quantities of Grapefruit Juice is officially restricted as it raises plasma levels, and caution is noted for Chinese patients taking high-dose Niacin.

Mechanism of Action

Sivastin, supplied as the Simvastatin prodrug (lactone), requires hydrolysis to yield the pharmacologically active beta-hydroxy acid form. This active molecule acts as a competitive inhibitor of the enzyme HMG-CoA reductase, which is the rate-limiting enzyme that catalyzes the initial step of the mevalonate pathway. By binding to the enzyme’s active site, the drug blocks the conversion of HMG-CoA into mevalonate, resulting in the reduction of the concentration of newly synthesized cholesterol and isoprenoid intermediates within the hepatocytes.

The resulting decrease in the internal concentration of cholesterol in liver cells initiates a homeostatic feedback mechanism. This process involves the increased expression and surface display of Low-Density Lipoprotein (LDL) receptors on the hepatocyte membrane. This upregulation functions as a primary mechanism for the catabolism of circulating LDL particles from the bloodstream. This systemic removal process reduces the overall concentration of low-density lipid particles in plasma, which is the key physiological consequence of the enzyme inhibition.

In addition to the hepatic lipid regulation, the reduced synthesis of isoprenoids contributes to extra-hepatic effects on the vascular system. By limiting the prenylation of small G-proteins (like Rho), this action modulates the stability and activity of endothelial Nitric Oxide Synthase (eNOS). This leads to increased bioavailability of Nitric Oxide (NO) at the endothelial surface and is associated with the modulation of cellular inflammatory and proliferative processes within the vessel wall.

Dosage and Administration Information

Official Administration Guidelines for Sivastin (Simvastatin)

Sivastin, containing the active substance Simvastatin, is an oral medication with administration governed by specific guidelines. Adherence to the official instructions for dose, timing, and route is essential to ensure proper use.

Feature Guideline
Route and Form The medication is intended for the oral route, supplied as film-coated tablets or an oral suspension.
Dosing Schedule (Adults) The typical adult dose range is 5 mg to 40 mg once daily. The usual starting dose is 20 mg or 40 mg in the evening. The 80 mg daily dose is restricted solely to patients who have been taking that dose chronically (12 months or more) without administration issues.
Frequency and Timing The dose must be taken once a day and is required to be taken in the evening. Dose adjustments should be made at intervals of 4 weeks or more to assess response.
Contextual Intake Tablets may be taken with or without food. If the oral suspension form is used, it should be taken on an empty stomach.
Population Rules For patients with severe renal impairment, the recommended starting dosage is 5 mg once daily. Adolescents (10–17 years) with HeFH start at 10 mg once daily, with a maximum dose of 40 mg.
Procedural Restrictions The Simvastatin dose must not exceed 10 mg once daily when co-administered with verapamil, diltiazem, or dronedarone, or 20 mg when co-administered with amiodarone, amlodipine, or ranolazine. If a dose is missed, it should be taken as soon as possible, but not doubled if it is near the next scheduled dose.

This structure defines a clear procedural framework that dictates the required route, titration frequency, and maximum dose limits when the medicine is used concurrently with specific agents.

Recent Clinical Evidence

Sivastin: Recent Clinical Evidence

Sivastin, a medication in the statin class, is primarily studied for its effect on lipid levels and the reduction of cardiovascular risk in various patient populations. It functions by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver.

Core Efficacy: Lipid Control and Outcomes

Clinical trials, including large-scale randomized studies, have consistently assessed Sivastin's role in altering cholesterol levels. The data indicate that the treatment is associated with a reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C), commonly referred to as "bad" cholesterol. It may also lead to an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in triglycerides.

Evidence from long-term studies exploring clinical outcomes supports the medication's use in high-risk patients. These studies have investigated the association between Sivastin use and a reduced incidence of major adverse cardiovascular events, such as non-fatal myocardial infarction and stroke, in patients with or without established coronary heart disease.

Comparative and Combination Research

Research has explored Sivastin both as a single agent and in combination with other lipid-modifying therapies, such as ezetimibe. Combination studies have focused on determining whether this approach achieves greater reductions in LDL-C or provides benefits in reducing certain atherogenic lipoprotein subfractions compared to Sivastin used alone or compared to other statins.

Safety and Tolerability Profile

Across clinical trials, Sivastin's safety profile has been routinely monitored. Commonly reported adverse events include mild gastrointestinal issues, headache, and muscle pain (myalgia). Serious but rare adverse events, such as severe muscle breakdown (rhabdomyolysis) and liver enzyme elevations, have been noted, particularly at higher doses or when combined with certain interacting medications. The trials included protocols for patient monitoring to detect potential adverse effects.

Key Studies & References

  1. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
  2. Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis
  3. SIMVASTATIN tablet, film coated (DailyMed/FDA Labeling)
  4. Cardiovascular disease: risk assessment and reduction, including lipid modification (NICE Guideline NG238)

Frequently Asked Questions (FAQ)

Common questions about Sivastin (FAQ)

Q: Is Sivastin the same type of medication as other common 'statin' drugs?

A: Yes. Official documents classify the active ingredient in Sivastin, Simvastatin, as an HMG-CoA reductase inhibitor. This is the class of medication commonly known as statins, which are used to help lower cholesterol.

Q: What happens if I miss taking Sivastin for a day?

A: Official patient instructions describe the direction for a missed dose: it is to be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. The instruction is to then continue with the regular dosing schedule, and a double dose should not be taken.

Q: What should I do if I suspect an interaction between Sivastin and another drug?

A: Regulatory patient information emphasizes the need for discussion with a healthcare provider or pharmacist if there is concern about an interaction. The safety guidance requires discussing all other medications, vitamins, and supplements before starting, stopping, or changing treatment with Simvastatin.

Q: Is there a generic version of Sivastin available?

A: Yes, the active ingredient in Sivastin is Simvastatin. A generic version, Simvastatin tablets, is widely available as documented in regulatory listings.

Q: Are the reported side effects the same for everyone who takes Sivastin?

A: No. The regulatory safety profile organizes potential adverse reactions based on their reported frequency in clinical data (such as Common, Uncommon, or Rare). This documentation indicates that not all patients experience the same effects, and most reported effects are uncommon or rare.

Q: Why might a doctor switch a patient from one statin to Sivastin, or vice versa?

A: Official documents describe that different statins have varying profiles regarding potential drug interactions, maximum dosage limits, and documented risks of certain side effects. These differences are factors that regulatory documents describe as considerations for treatment management.

Q: What kind of monitoring is done after starting Sivastin?

A: Liver function blood tests are documented as necessary components of monitoring before starting the medication and periodically during treatment, as part of checking liver function. Monitoring may also include tests for muscle enzymes if muscle-related symptoms occur.

Q: What happens if I suddenly stop taking Sivastin?

A: Official patient information states that the decision to stop the medication must be made in consultation with a healthcare provider. Discontinuing treatment without professional supervision may cause the underlying condition to worsen.

Q: Is headache a common complaint when starting Sivastin?

A: Headache is listed in official documents as one of the commonly reported side effects of this medication.

Q: How quickly does Sivastin start working to change lab results?

A: Clinical evidence indicates that the therapeutic effect, such as the reduction in Low-Density Lipoprotein (LDL-C) cholesterol levels, typically begins within the first few weeks of starting treatment.

Q: What are the most commonly reported side effects of Sivastin?

A: Based on official safety profiles, commonly reported adverse events include headache, constipation, stomach pain, and nausea.

Q: Can I drink alcohol while taking Sivastin?

A: Regulatory information advises that using this medication with substantial quantities of alcohol may increase the risk of liver problems. Official guidance notes that the use of substantial quantities of alcohol should be limited while being treated.

Q: Does taking Sivastin mean I don't have to change my diet?

A: No. Official labeling states that Simvastatin is indicated for use as an adjunct to diet to reduce cholesterol. This means it is intended to be used in combination with following a proper, lipid-lowering diet.

Q: Does Sivastin interact with commonly used over-the-counter pain relievers?

A: Current regulatory interaction profiles do not specifically list common nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, as prohibited co-administrations. However, the official stance is to discuss all concurrent medications with a healthcare professional.

Q: What are the signs of a serious, but rare, side effect from Sivastin?

A: Signs of serious but rare side effects documented in patient materials include unexplained muscle pain or weakness, particularly if accompanied by fever or dark urine. Another potential sign is yellowing of the skin or eyes (jaundice), which may indicate liver issues.

Q: Are there any mental side effects like confusion or memory issues associated with Sivastin?

A: Regulatory patient information notes that cognitive impairment, which may include memory loss, forgetfulness, and confusion, has been reported with the use of this class of medication.

Q: Is Sivastin a blood thinner?

A: Sivastin is a statin that works to lower cholesterol levels. It is not classified as a blood thinner, although the drug label notes that it may potentiate the effect of Coumarin Anticoagulants (a type of blood thinner) when they are taken together.

Q: Does Sivastin interact with vitamins or herbal supplements?

A: Official warnings note that the herbal supplement St. John's wort may reduce the effectiveness of Simvastatin. Additionally, caution is noted for concomitant use with lipid-modifying doses of Niacin, and the use of all supplements requires discussion with a healthcare provider.

Q: Are there any skin reactions or rashes linked to taking Sivastin?

A: Skin reactions and rashes are noted as possible adverse events in regulatory documents. These include itchy or red skin and, rarely, severe skin reactions such as erythema multiforme.

Q: What research themes are commonly explored regarding the use of Sivastin?

A: Key research themes formally described in clinical studies focus on its effects on total cholesterol and LDL-C reduction. They also explore the associated reduction in the incidence of major adverse cardiovascular events, such as non-fatal heart attack and stroke.

Q: Do children or teenagers ever use Sivastin?

A: Simvastatin is approved for use in pediatric patients (adolescents) aged 10 years and older who have Heterozygous Familial Hypercholesterolemia (HeFH), provided specific prescribing conditions defined in official documents are met.

Q: Does Sivastin have potential interactions with common antacids?

A: Official guidance states that when co-administered with Bile Acid Sequestrants, a class of cholesterol-lowering drug, Simvastatin must be taken at least two hours before or four hours after the sequestrant. There is no specific official warning against common non-sequestrant antacids.

Q: Can Sivastin affect my sleep?

A: Some patient information documents indicate that certain nervous system effects, such as vertigo or dizziness, have been reported. Some sources also mention that the medication may cause sleepiness.

Q: Does taking Sivastin have any impact on blood sugar levels?

A: Official warnings note that increases in hemoglobin A1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.

Q: Can people who are physically active or exercise heavily use Sivastin?

A: The regulatory safety profile notes that patients should report unusual muscle pain or weakness, particularly if accompanied by fever, due to the risk of muscle injury. Official labeling does not include specific restrictions regarding exercise itself.

How should Sivastin be stored and disposed of?

Storage Requirements

Simvastatin tablets must be stored in a closed container at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept away from excess heat and moisture, and protected from direct light to maintain its stability.

Storing the medicine in a bathroom is discouraged. It must also be kept from freezing.

Child Safety and Disposal

It is a mandatory regulatory requirement to keep this medicine out of the sight and reach of children.

Unneeded or outdated medicine should not be kept. For proper disposal, individuals must consult a healthcare professional or pharmacist. The official guidance requires that the product not be thrown away via wastewater or household waste, and the disposal process must align with environmental protection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sivastin found in:

A-Z Index: